NCT00147615

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 6 Years – 16 Years
• Healthy volunteers: Not accepted

Summary

To assess the long-term safety and toleration of eplerenone in the children aged 6 to 16 years with high blood pressure. The study will last at least 1 year and about 140 patients will participate.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Eplerenone

Timeline

• Start date: 2004-10-01
• Completion: 2006-06-01
• First posted: 2005-09-07
• Last updated: 2020-12-22

Locations

21 sites across 3 countries: United States, India, Russia